AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Gastrocnemius Myofascial Release in Females With Knee Osteoarthritis

RecruitingNAAges 45 Years - 55 YearsFemaleCairo University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to determine whether gastrocnemius myofascial release is effective in reducing pain and improving physical function in females with knee osteoarthritis. The main question this study aims to answer are: * Does adding gastrocnemius MFR to conventional physical therapy treatment influence pain, physical function, foot posture, and knee disability compared to conventional physical therapy treatment and sham MFR in knee osteoarthritis? * Participants receive gastrocnemius myofascial release treatment or sham gastrocnemius myofascial release treatment for 3 times weekly for 4 weeks for both groups.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients' ages ranged between 45 and 55 years . * BMI โ‰ค35 * Patients with a diagnosis of primary KOA according to the American College of Rheumatology classification at the screening visit . * Onset of symptomatic knee osteoarthritis of โ‰ฅ3 months * Patients with grade II and III OA of the Kellgren and Lawrence system for classification of osteoarthritis . * At least one active trigger point in GM * If both knees were diagnosed as OA, the most affected one was selected. * Current pain intensity on the Visual Analogue Scale (VAS) โ‰ฅ4/10. * Subjects have sufficient cognition that enables them to understand the requirements of the study, comply with the study procedures, and visit schedule. * Diagnostic Criteria of KOA A diagnosis of knee osteoarthritis was made when knee pain is present, plus Osteophytes on radiographs, plus at least 1 of the following 3: * Age \> 50 years * Morning stiffness \< 30 minutes * Crepitus on active motion Exclusion Criteria: * Patients with any previous knee surgeries or lower limb fractures. * Chronic inflammatory diseases such as rheumatoid arthritis. * Signs of moderately significant knee synovitis include a warm and swollen (red) knee * History and/or physical examination findings compatible with knee internal derangement (e.g, positive Thessaly test). * Pregnancy * Patients who had undergone arthroscopy or treatment with intra-articular hyaluronic acid during the previous 6 months . * Use of NSAIDs one week before the screening visit . * Orthopedic diseases, or congenital musculoskeletal deformities, or neurological disorders that may affect or interfere with the therapeutic effect. * Participated in other intervention studies (strength training program or physiotherapy treatment for knee osteoarthritis) in the current period and the past 6 months . * Habitual use of psychotropic or narcotic analgesics for โ‰ฅ1 week within 8 weeks prior to screening .
๐Ÿ’Š

What it tests

  • GASTROCNEMIUS MYOFASCIAL RELEASE
  • sham Gastrocnemius MYOFASCIAL RELEASE
๐Ÿ“

Where

1 site
Faculty of Physical Therapy, Cairo University
Giza, Egypt
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy